Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
Key Highlights
- ➤12-month survival estimated at 62.0% among 1,630 severe AH patients
- ➤30-day rehospitalization reached 31.4% after severe alcohol-associated hepatitis hospitalization
- ➤12-month rehospitalization estimated at 69.1% in severe AH patients
- ➤12-month liver transplantation rate estimated at 8.5%
- ➤Bausch Health’s Salix will present severe AH research at The Liver Meeting 2026
Expert Statements
Jonathan Sadeh, Executive Vice President, Chief Medical Officer and Head of R&D, Bausch Health
“The findings of this study highlight the substantial burden of advanced liver disease and the urgent unmet need facing patients hospitalized with severe alcohol-associated hepatitis”
Jonathan Sadeh, Executive Vice President, Chief Medical Officer and Head of R&D, Bausch Health
“Generating real-world evidence is essential to better understanding patients' needs and informing research priorities as we work toward improving outcomes for people living with serious liver disease.”
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 PR Newswire
LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting(®) 2026 , November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
Get started
Create a free account to read the full story.